PFEPfizerNot started yet
A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer
Early Breast Cancer · Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 3,800 (planned)
- Started
- Dec 1, 2026
- Main results expected
- Apr 13, 2032
- Fully finished
- Aug 20, 2042
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Invasive Breast Cancer Free Survival (iBCFS)
Measured over: Baseline until recurrence up to 64 months
Invasive Disease Free Survival (iDFS)
Measured over: Baseline until recurrence up to 64 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07890597 · record last updated 2026-10-22 · checked 2026-11-09 15:36 UTC